Microfluidic hemophilia models using blood from healthy donors.

ABSTRACT:

Background

Microfluidic clotting assays permit drug action studies for hemophilia therapeutics under flow. However, limited availability of patient samples and Inter-donor variability limit the application of such assays, especially with many patients on prophylaxis.

Objective

To develop approaches to phenocopy hemophilia using modified healthy blood in microfluidic assays.

Methods

Corn trypsin inhibitor (4 µg/mL)-treated healthy blood was dosed with either anti-factor VIII (FVIII; hemophilia A model) or a recombinant factor IX (FIX) missense variant (FIX-V181T; hemophilia B model). Treated blood was perfused at 100 s^-1 wall shear rate over collagen/tissue factor (TF) or collagen/factor XIa (FXIa).

Results

Anti-FVIII partially blocked fibrin producti

SUBMITTER: Yu X 

PROVIDER: S-EPMC6971334 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature